Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
NCT05912621 on ClinicalTrials.gov · last registry update 2024-12-04
Recruiting now, toward 66 participants. Due to report June 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in Adipocyte Size. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 9 November 2023 — 2 years so far. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- Stanford University
- Sponsor type
- Other
- Enrollment
- 66
- Started
- 2023-11-09
- Primary completion
- 2028-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Adipocyte Size
Conditions studied
Obesity · Overweight and Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.